August 20, 2017 3:10 PM ET

Healthcare Equipment and Supplies

Company Overview of TearScience, Inc.

Company Overview

TearScience, Inc. is a medical device company that engages in identifying, diagnosing, and treating meibomian gland disease (MGD), which is the cause of dry eye. The company focuses on the early detection and treatment of prevalent, chronic, and progressive MGD. It develops LipiFlow Activator, a single-use sterile device that delivers automated therapeutic energies to each meibomian gland while protecting the delicate structures of the patient’s eye; and LipiScan, a gland imager that allows eye care professionals to evaluate meibomian glands in practices. The company was formerly known as Kolis Scientific, Inc. and changed its name to TearScience, Inc. in July 2005. TearScience, Inc. was fou...

5151 McCrimmon Parkway

Suite 250

Morrisville, NC 27560

United States

Founded in 2005





Key Executives for TearScience, Inc.

Chief Executive Officer and President
Co-Founder and Chief Technical Officer
Chief Financial Officer
Vice President of R & D, Manufacturing & Service
Vice President of Marketing & Market Development
Compensation as of Fiscal Year 2017.

TearScience, Inc. Key Developments

TearScience Introduces LipiFlow® Activator II

TearScience announced the release of the LipiFlow Activator II treatment disposable. The newly released disposable maintains the same level of quality and efficacy as the original Activator. LipiFlow's Activator consists of the scleral lens heating surface, the shield structure and the pulsation bladders, all of which directly interface with the patient oculus. The Activator II meets the same standard for sterility as the original Activator. Activator II is used with a separate, semi-permanent cable, which remains connected to the LipiFlow Console. The LipiFlow System now includes a reusable cable that reduces waste. With roughly five million tons of institutional medical waste being dumped in US landfills each year, TearScience to introduce this new, waste-reducing Activator II, which is compatible with existing LipiFlow systems. LipiFlow has consistently demonstrated superior efficacy in more than 30 peer reviewed studies, now having shown sustained effect of increased mean meibomian gland secretions and improved mean dry eye symptoms from a single application. Increased recognition of the important role MGD plays in compromising the ocular surface and of new accessible pricing from TearScience is resulting in a transformation of patient care and renewed practice growth.

TearScience Names Edward J. Holland to Board of Directors

TearScience announced the addition of Edward J. Holland, MD, to its board of directors. Dr. Holland is a leader in the field of Cornea and Ocular Surface Health.

TearScience, Inc. Introduces LipiScan

TearScience announced the release of LipiScan, the first and only dedicated high definition (HD) gland imager that allows eye care professionals (ECPs) to efficiently evaluate meibomian glands in busy practices. The new rapid imager was created with end users in mind. Fast and intuitive, LipiScan harnesses patented dynamic meibomian imaging (DMI) technology to produce high definition images of meibomian glands. LipiScan allows ECPs to assess meibomian gland structure during routine workups in any practice setting. The introduction of LipiScan will allow busy practices to efficiently integrate assessment of meibomian glands and do so at an affordable price. MGD is a prevalent chronic, obstructive and progressive disease that impacts the tear film, visual performance and ocular comfort. LipiFlow treatment for MGD is supported by significant science. A review of 31 sponsored and unsponsored peer-reviewed reports demonstrated that a single LipiFlow treatment typically improves mean meibomian gland secretions while reducing mean patient-reported symptom scores over sustained periods.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TearScience, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at